|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Selexis partners NRC-BRI to offer human cell line for contract research
|
|
Selexis
: 17 July, 2008 (Company News) |
|
|
Selexis has partnered with the National Research Counsel of Canada's Biological Research Institute (NRC-BRI) to offer the NRC-BRI HEK293 cell technologies for the contract development of high-performance stable human cell lines enabled by the Selexis Genetic Element and Selexis SURE Cell Line Development Services. |
|
HEK293 cells are the most widely used human cell line in biotechnology industry and the only human cell line used for the bioproduction of an FDA approved biopharmaceutical drug.
Xigrils, a recombinant form of human Activated Protein C, is marketed by Eli Lilly for the treatment of severe sepsis. Xigrils was approved by US-FDA in November of 2001 and is produced using HEK293 cells.
Dr Igor Fisch, president and chief executive officer of Selexis, commented: 'Partnering with the NCR-BRI to offer their well characterized human cell line is a perfect complement to our well developed and proven CHO platform, especially considering the fact that HEK293 cells have already been approved for the production of a recombinant protein drug.'
'For over a decade Dr Amine Kamen and his team of researchers at the BRI have done an outstanding job of developing their HEK293 program for large scale production purposes and now Selexis has the opportunity to make it more widely available with improved performance characteristics using our Selexis Genetic Element technology and our Selexis SURE Cell Line Development Services.'
'This partnership will further reinforces Selexis' position as world leader of DNA-based technologies that significantly improve the long-term and stable expression of transgenes in a variety of eukaryotic host systems.'
Dr Pierre-Alain Girod, chief scientific officer of Selexis, commented: 'This combined program will be highly desirable to biotech companies needing the rapid development of a high performance cell line expressing proteins with human glycosylation patterns. This new platform will be a viable option to our CHO programme for more difficult to express proteins.'
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
